Cardiovascular disease and stroke together account for roughly one in four deaths in Singapore each year, according to Ministry of Health (MOH) Principal Causes of Death data. The statistic is familiar. What is less visible is the biological mechanism that builds toward those events across years or decades: chronic, low-grade inflammation. High-sensitivity C-reactive protein (HS-CRP) is the blood marker that makes that process measurable — early enough to matter.
Most Singaporeans who attend a health screen at a polyclinic will receive either no CRP result or a standard one. The standard CRP assay is designed to detect acute inflammation from infection or injury and starts signalling reliably above 5–10 mg/L. It is the right tool for diagnosing illness. It is the wrong tool for tracking the slow, systemic inflammatory activity that quietly damages arteries over decades. HS-CRP measures at ten times the precision — down to 0.1 mg/L — and that sensitivity gap is where longevity medicine begins.
Why Chronic Inflammation Matters for Longevity
Inflammation exists on a spectrum. The acute version — fever, localised swelling, the redness after an injury — is a tightly coordinated immune response that resolves within days and leaves biological systems largely intact. The chronic version is something different: a persistent, low-level activation of immune signalling with no clear trigger and no natural resolution. That distinction carries significant biological consequences over time.
Preliminary research indicates that sustained low-grade immune activation — sometimes termed “inflammaging,” describing the intersection of inflammation and biological ageing — is linked to cumulative cellular damage, arterial stiffening, and the gradual erosion of tissue function associated with accelerated biological age. The inflammaging framework is gaining traction across geroscience research, including work published in Nature Medicine, though the causal pathways in humans are still being mapped. What is far better established is the cardiovascular signal downstream: elevated HS-CRP in otherwise healthy individuals predicts major cardiovascular events independently of cholesterol and blood pressure.
The mechanism runs through cytokines — signalling proteins, primarily interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) — that prompt the liver to produce CRP as part of the acute-phase response (the liver's rapid reaction to immune activation signals). In the chronic state, these cytokines are mildly but persistently elevated, generating a low-level CRP signal that standard assays miss entirely. HS-CRP captures it at clinical resolution.
How HS-CRP Measures Chronic Inflammation
C-reactive protein is a pentameric protein — five identical subunits arranged in a ring — synthesised almost entirely by the liver. It is part of the innate immune system, binding to damaged cell membranes and certain microbial markers to flag them for removal. In individuals with low systemic inflammation, resting CRP concentrations sit well below 1 mg/L.
Standard CRP assays have an effective lower detection limit of around 5–10 mg/L. Below that floor, measurement error is large enough to make the result clinically uninformative. HS-CRP uses a more sensitive immunoassay technique that reliably measures down to 0.1 mg/L. That difference allows a clinician — and you — to distinguish between a result of 0.3 mg/L and one of 2.5 mg/L, two readings that a standard assay would both report as “within normal limits.”
The test itself is a single blood draw. Fasting is not required for the HS-CRP result specifically, though your clinician will typically pair it with a fasted lipid and glucose panel. Results are reported in milligrams per litre (mg/L). The complexity lies not in the procedure but in interpreting where your number sits against both the clinical and the longevity-optimised benchmarks — and understanding what the gap between them means.
READ ALSO: ApoB Testing in Singapore: The Lipid Marker Your Standard Panel Misses
The Evidence: HS-CRP and Cardiovascular Ageing
The research confirms that HS-CRP is an independent predictor of major cardiovascular events. The Women's Health Study, published in the New England Journal of Medicine in 2002 and following nearly 28,000 initially healthy women over eight years, found that HS-CRP was a stronger predictor of first cardiovascular events — including myocardial infarction and stroke — than LDL cholesterol. Women in the highest HS-CRP quartile had more than twice the event rate of those in the lowest quartile, independent of cholesterol level, blood pressure, and other classical risk factors.
The JUPITER trial, also published in the New England Journal of Medicine in 2008, provided one of the clearest demonstrations of HS-CRP's clinical relevance. Enrolling approximately 17,800 men and women with normal LDL cholesterol (below 130 mg/dL) but elevated HS-CRP (at or above 2 mg/L) — a profile that standard lipid screening classifies as low-risk — the trial confirmed that the elevated inflammatory signal independently drove cardiovascular events in this otherwise low-LDL population. Treatment strategies targeting both inflammatory burden and lipid levels produced significantly lower event rates than those addressing lipids alone.
The research suggests a gradient rather than a threshold: even within the clinically “low-risk” category (below 1 mg/L), lower values are associated with better long-term outcomes. The Framingham Heart Study, tracking cardiovascular risk factors across multiple generations, consistently shows HS-CRP as an additive predictor when layered on top of cholesterol, blood pressure, and smoking status — most usefully for individuals at intermediate risk by standard metrics.
For Singapore specifically, the Health Promotion Board (HPB) and MOH have progressively updated their cardiovascular risk frameworks to extend beyond LDL, reflecting international evidence that standard lipid panels systematically underestimate risk in a meaningful subset of patients.
READ ALSO: Fasting Glucose vs HbA1c: Reading Your Metabolic Risk at a Singapore Polyclinic
Standard Clinical Ranges vs Longevity-Optimised: The Gap
The cardiovascular risk categories most clinicians use globally were established in a 2003 scientific statement by the American Heart Association (AHA) and the US Centers for Disease Control and Prevention (CDC). They divide HS-CRP results into three tiers based on population-level cardiovascular risk. The longevity-optimised target is drawn from the lower portion of the low-risk category — the range that characterises the lowest-event cohorts in large prospective cardiovascular datasets.
| Category | Standard Clinical Range (AHA/CDC) | Longevity-Optimised Target |
|---|---|---|
| Low cardiovascular risk | <1.0 mg/L | <0.7 mg/L |
| Moderate cardiovascular risk | 1.0–3.0 mg/L | Below this range |
| High cardiovascular risk | >3.0 mg/L | Below this range |
| Active inflammation / likely infection | >10 mg/L | Retest after resolution |
The gap worth naming explicitly: a result of 2.6 mg/L sits in the moderate-risk category and will often pass without clinical comment — it is not zero, but it is not flagged as requiring immediate action by most standard protocols. From a longevity standpoint, that result represents approximately four times the inflammatory signal of a well-functioning baseline. The difference between “not yet disease” and “optimised” is the space HS-CRP testing makes visible.
The longevity-optimised target of below 0.7 mg/L is not a guaranteed biological outcome — age, genetics, and pre-existing conditions all influence resting HS-CRP. It is a benchmark drawn from where the lowest-event cohorts in cardiovascular studies consistently cluster. As the Mayo Clinic notes, any single HS-CRP result must be read alongside the full clinical picture — particularly recent illness or injury, which transiently elevates the marker and makes the reading unrepresentative of the chronic baseline.
READ ALSO: Homocysteine and Cardiovascular Risk: The Biomarker Singapore Clinicians Often Skip
How to Test HS-CRP at a Singapore Polyclinic
HS-CRP is available within Singapore's public healthcare system but requires a specific request. It is not part of the default screening panel.
Screen for Life: The HPB's Screen for Life (SFL) programme offers subsidised cardiovascular and metabolic screening at polyclinics and CHAS (Community Health Assist Scheme) GP clinics for eligible Singaporeans. The standard SFL panel covers total cholesterol, HDL, LDL, triglycerides, fasting glucose, and blood pressure. HS-CRP is not included by default. You can raise it with your polyclinic doctor as an add-on; whether it is ordered will depend on your clinician's assessment of your risk profile.
CHAS subsidies: CHAS provides means-tested subsidies at participating GP clinics. Subsidies cover the standard consultation and panel items. HS-CRP as an add-on typically falls outside the standard subsidised scope and is charged at the institutional lab rate — approximately $15–$30 SGD (2026) at public polyclinics. Confirm current pricing at your institution before your visit.
Private labs: For a broader longevity biomarker panel, private clinical labs at major health systems and independent diagnostic centres offer HS-CRP as a standalone or bundled test, typically at $25–$50 SGD (2026) as part of a wider cardiovascular panel.
What to request: Ask explicitly for high-sensitivity CRP, not standard CRP. Confirm that results will be reported in mg/L to at least one decimal place. A result returned as “within normal limits” from a standard assay tells you nothing about cardiovascular or longevity risk if the test cannot resolve below 5 mg/L.
Timing and accuracy: Do not test during or within two to three weeks of an acute illness, dental procedure, injury, or surgery — all of which transiently elevate HS-CRP and render the result unrepresentative of the chronic baseline. According to Cleveland Clinic guidance, a result above 10 mg/L should prompt a retest after ruling out acute illness rather than being treated directly as a chronic inflammation finding.
READ ALSO: Vitamin D Testing in Singapore: What Your Result Means for Immune and Musculoskeletal Health
Interpreting Your Results: What Each Level Means
A useful HS-CRP result requires context: your age, overall cardiovascular risk profile, any recent acute events, and other biomarkers. What follows is a practical framework; your clinician applies it to your specific situation.
Below 0.7 mg/L: The longevity-optimised range. This indicates a low systemic inflammatory load at the time of testing. The priority is sustaining the conditions that support this level — aerobic fitness, dietary quality, sleep quantity, and body composition — and retesting annually to track stability over time.
0.7–1.0 mg/L: Technically within the standard low-risk category but above the longevity-optimised target. Worth examining modifiable contributors: sleep quality, visceral fat, aerobic capacity, dietary fibre intake, and alcohol consumption. Retest in three to six months after any intentional lifestyle change to quantify the effect.
1.0–3.0 mg/L: Moderate cardiovascular risk per AHA/CDC guidelines. The research suggests that sustained levels in this range carry meaningful long-term cardiovascular risk independently of LDL, as the JUPITER trial data demonstrated. A conversation with your clinician about a fuller cardiovascular risk panel — including ApoB, Lp(a) (lipoprotein(a), a genetically determined lipid particle linked to arterial inflammation), and fasting insulin — is appropriate. Do not self-manage a finding at this level without clinical input.
Above 3.0 mg/L (persistent, not attributable to acute illness): High cardiovascular risk by standard guidelines. This warrants clinical investigation into underlying contributors, which may include visceral obesity, obstructive sleep apnoea, periodontal disease, metabolic dysfunction, or autoimmune conditions — all of which your clinician can assess systematically.
The research suggests that lifestyle factors carry a measurable effect on HS-CRP across all ranges. Consistent aerobic exercise, dietary patterns structured around vegetables, fish, whole grains, and legumes, sustained visceral fat reduction, and adequate sleep (seven to nine hours per night) appear as modifiable correlates of lower HS-CRP in large observational datasets reviewed by the Harvard T.H. Chan School of Public Health. For any specific programme, consult your clinician to rule out non-lifestyle causes before pursuing lifestyle modification in isolation.
Singapore's hawker environment offers genuine options within these parameters. Dishes structured around fish, tofu, and vegetables — yu choy with fish soup, yong tau foo, steamed fish at most coffee shops — fit the broad dietary pattern associated with lower inflammatory burden. Overall dietary pattern across multiple meals matters more than any individual dish, and sodium and fat content across the full day is relevant context.
This Article Covers One Piece of the System
HS-CRP is one signal in a system of interconnected biomarkers. Understanding your inflammatory baseline is foundational, but it does not stand alone: ApoB, fasting insulin, HbA1c (glycated haemoglobin — a measure of average blood glucose over three months), and cortisol all intersect with the same underlying biological mechanisms. This article covers one piece of the system. The 30-Day Biohacking Starter Guide covers all of it, with a day-by-day protocol built specifically for Singapore.
HS-CRP Testing FAQ
Is HS-CRP the same as a standard CRP test?
Both measure the same protein, but at different sensitivity levels. A standard CRP test reliably detects concentrations above 5–10 mg/L and is designed to identify acute inflammation from infection or injury. HS-CRP detects concentrations down to 0.1 mg/L and is the appropriate test for cardiovascular and longevity risk assessment. Specify “high-sensitivity CRP” explicitly when requesting the test — the shorthand “CRP” will default to the standard assay in most clinical settings.
Does HS-CRP testing require fasting?
Not for the HS-CRP result itself. However, clinicians typically pair it with a fasted lipid panel and blood glucose measurement, which do require fasting. Confirm what your clinician recommends before your appointment so you can prepare appropriately for the full draw.
Can lifestyle changes lower my HS-CRP?
The research suggests yes, where elevated HS-CRP reflects modifiable lifestyle factors rather than an underlying medical condition. Regular aerobic exercise, dietary patterns higher in vegetables, fish, and fibre, sustained reduction of visceral fat, and improved sleep quality consistently appear as correlates of lower HS-CRP in observational data. The magnitude of effect varies by individual. Your clinician should rule out non-lifestyle causes first before you pursue lifestyle modification as the primary strategy.
How often should I retest?
Annual testing is a reasonable baseline once you have established your resting level. If you are making deliberate lifestyle or medical interventions aimed at lowering an elevated result, retesting at three to six months provides more actionable feedback. Do not test during or within two to three weeks of an acute illness or injury.
Is HS-CRP covered under Screen for Life or CHAS in Singapore?
The standard Screen for Life panel does not include HS-CRP. You can request it as an add-on at your polyclinic consultation, which your doctor may order if your risk profile supports it. CHAS subsidies cover standard panel items; HS-CRP as an add-on is typically charged at the institutional lab rate. Confirm current pricing directly with your polyclinic or CHAS GP clinic, as fees are subject to change.
